VANCOUVER, British Columbia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the release of its first proprietary product, Comfort, through the Company’s wholly-owned subsidiary Vergence Naturals (“Vergence”).
Comfort, a brand-new proprietary nutraceutical, which contains Alpinia Galangal and Capsicum Annuum, was developed by Abattis’ research scientists to activate the endocannabinoid system (“ECS”) and nourish endorphin release in response to pain. Comfort is manufactured in accordance with Canadian Natural Health Products monographs and the US Food and Drug Administration’s Current Good Manufacturing Practice regulations.
Comfort Extra Strength, the second addition to the Comfort product line, is set to be released to the public in mid-January 2019 and will be enhanced with hemp-based phytocannabinoids, with a specific focus on cannabidiol (CBD).
“The discovery of the ECS has opened the door to understanding how our body works,” stated Dr. Brazos Minshew, MSc, ND and President of the Abattis’ Medical Advisory Board. “The ECS teaches us how cannabis, as well as other foods and spices, impacts our pain receptors and every other aspect of mind-body wellness. We are now able to link the known effect of cannabinoids with the new understanding of how this massive system works to keep us comfortable and balanced.”
“Comfort by Vergence nourishes the ECS with medicinal plants that do not contain tetrahydrocannabinol (THC). Comfort meets a real need to increase vitality, energy and mobility. In short, Comfort supports a healthy mind and body by nourishing the ECS,” added Dr. Minshew.
“This marks yet another significant milestone for Abattis,” stated Rob Abenante, President and CEO of Abattis. “With the launch of Comfort, Abattis continues to focus on revenue generating activities, which we are confident will drive shareholder value.”
“We are particularly proud of the work we have done with Comfort as it will provide a natural cannabinoid solution to all those suffering from all forms of pain,” added Mr. Abenante.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
Robert Abenante, President & CEO
For more information, please visit the Company’s website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at firstname.lastname@example.org. Abattis’ investor relations are managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One Communications Inc. (“Canada One”) is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected release of Comfort Extra Strength In mid-January 2019 and that the release of Comfort and Comfort Extra Strength will translate to increased shareholder value. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties including: that the Company will not be in a position to release Comfort Extra Strength by mid-January 2019, that the success and sales of Comfort and Comfort Extra Strength by Vergence will not be as expected, in addition to other market factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.